Letter to the Editor From Hallanger Johnson and El-Haddad: “Yttrium-90 Selective Internal Radiation Therapy Plus Cryoablation for Recurrent Adrenocortical Carcinoma With Liver Metastases”

We read with interest the recent article by Lin et al [1], sharing their experience with yttrium-90 (Y-90) for treatment of adrenocortical carcinoma (ACC). We fully embrace the opportunity to use any and all available treatment options for this rare and devastating illness for which surgical treatments are often the only chance for cure. We wanted to bring our experience and published case to the attention of the authors who state that only 2 cases have been reported. We published our experience [2] in 2021 using Y-90 resin microspheres to treat a gentleman with ACC metastatic to the liver. Our patient opted for surgical resection 7 months after his Y-90 therapy for liver metastasis per multidisciplinary team discussion. At pathology, there was no viable tumor in the pathology specimen, including the margins, providing confirmation of successful treatment of his hepatic metastases. Our case is the only published report with proven complete pathologic response post Y-90 radioembolization in a patient with ACC liver metastases. We believe this is an important option to consider for patients with metastatic ACC which is challenging to treat with effective systemic therapy options.

Disclosures

J.H.J.: HRA Pharma—Consulting fee; G.E.-H.: Bayer HealthCare—Consulting Fee, Boston Scientific Corporation—Consulting Fee, Canon Medical Systems Corporation—Consulting Fee, Novartis Pharmaceuticals Corporation—Consulting Fee, Terumo Medical Corporation—Consulting Fee.